TY - JOUR
T1 - A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy
AU - Dhar, Arti
AU - Venkadakrishnan, Jegadheeswari
AU - Roy, Utsa
AU - Vedam, Sahithi
AU - Lalwani, Nikita
AU - Ramos, Kenneth S.
AU - Pandita, Tej K.
AU - Bhat, Audesh
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AB acknowledges the financial support from the Indian Council of Medical Research (Grant nos. 5/10/15/CAR-SMVDU/2018-RBMCH and 6719/2020-DDl/BMS) and AD acknowledges the financial support from the Indian Council of Medical Research (Grant no. 6719/2020-DDl/BMS). KSR acknowledges the financial support from the Governors University Research Initiative of Texas.
Publisher Copyright:
© The Author(s), 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Diabetic cardiomyopathy (DCM) is characterized by structural and functional abnormalities in the myocardium affecting people with diabetes. Treatment of DCM focuses on glucose control, blood pressure management, lipid-lowering, and lifestyle changes. Due to limited therapeutic options, DCM remains a significant cause of morbidity and mortality in patients with diabetes, thus emphasizing the need to develop new therapeutic strategies. Ongoing research is aimed at understanding the underlying molecular mechanism(s) involved in the development and progression of DCM, including oxidative stress, inflammation, and metabolic dysregulation. The goal is to develope innovative pharmaceutical therapeutics, offering significant improvements in the clinical management of DCM. Some of these approaches include the effective targeting of impaired insulin signaling, cardiac stiffness, glucotoxicity, lipotoxicity, inflammation, oxidative stress, cardiac hypertrophy, and fibrosis. This review focuses on the latest developments in understanding the underlying causes of DCM and the therapeutic landscape of DCM treatment.
AB - Diabetic cardiomyopathy (DCM) is characterized by structural and functional abnormalities in the myocardium affecting people with diabetes. Treatment of DCM focuses on glucose control, blood pressure management, lipid-lowering, and lifestyle changes. Due to limited therapeutic options, DCM remains a significant cause of morbidity and mortality in patients with diabetes, thus emphasizing the need to develop new therapeutic strategies. Ongoing research is aimed at understanding the underlying molecular mechanism(s) involved in the development and progression of DCM, including oxidative stress, inflammation, and metabolic dysregulation. The goal is to develope innovative pharmaceutical therapeutics, offering significant improvements in the clinical management of DCM. Some of these approaches include the effective targeting of impaired insulin signaling, cardiac stiffness, glucotoxicity, lipotoxicity, inflammation, oxidative stress, cardiac hypertrophy, and fibrosis. This review focuses on the latest developments in understanding the underlying causes of DCM and the therapeutic landscape of DCM treatment.
KW - cardiovascular diseases
KW - diabetic cardiomyopathy
KW - fibrosis
KW - glucotoxicity
KW - inflammation
KW - insulin signaling
KW - lipotoxicity
KW - oxidative stress
KW - type 2 diabetes
KW - Heart
KW - Signal Transduction
KW - Humans
KW - Diabetes Mellitus
KW - Myocardium/metabolism
KW - Inflammation/drug therapy
KW - Diabetic Cardiomyopathies/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85179310288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179310288&partnerID=8YFLogxK
U2 - 10.1177/17539447231210170
DO - 10.1177/17539447231210170
M3 - Review article
C2 - 38069578
AN - SCOPUS:85179310288
SN - 1753-9447
VL - 17
SP - 17539447231210170
JO - Therapeutic Advances in Cardiovascular Disease
JF - Therapeutic Advances in Cardiovascular Disease
ER -